Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 244

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Consensus on molecular imaging and theranostics in neuroendocrine neoplasms

Open access
Ambrosini, Valentina, Kunikowska, Jolanta, Baudin, Eric, Bodei, Lisa, Bouvier, Catherine, Capdevila, Jaume, Cremonesi, Marta, de Herder, Wouter W., Dromain, Clarisse, Falconi, Massimo, Fani, Melpomeni, Fanti, Stefano, Hicks, Rodney J., Kabasakal, Levent, Kaltsas, Gregory, Lewington, Val, Minozzi, Silvia, Cinquini, Michela, Öberg, Kjell, Oyen, Wim. J.G., O'Toole, Dermot, Pavel, Marianne, Ruszniewski, Philippe, Scarpa, Aldo, Strosberg, Jonathan, Sundin, Anders, Taïeb, David, Virgolini, Irene, Wild, Damian, Herrmann, Ken, Yao, James·2021·European Journal of Cancer

Abstract

Nuclear medicine plays an increasingly important role in the management neuroendocrine neoplasms (NEN). Somatostatin analogue (SSA)-based positron emission tomography/computed tomography (PET/CT) and peptide receptor radionuclide therapy (PRRT) have been used in clinical trials and approved by the European Medicines Agency and Food and Drug Administration. EANM Focus 3 performed a multi-disciplinary Delphi process to deliver a balanced perspective on molecular imaging and radionuclide therapy in well-differentiated neuroendocrine tumours (NET). Several societies’ guidelines address NEN management, however, many issues are still debated, due to both the difficulty in acquiring strong clinical evidence in a rare and heterogeneous disease and the different availability of diagnostic and therapeutic options across countries. EANM Focus 3 reached consensus on employing [68Ga]Ga-DOTA-SSA PET/CT with diagnostic CT or magnetic resonance imaging for unknown primary NET detection, metastatic NET, NET staging/restaging, suspected extra-adrenal pheochromocytoma/paraganglioma and suspected paraganglioma. Consensus was reached on employing [18F]FDG PET/CT in neuroendocrine carcinoma, G3 NET and in G1–2 NET with mismatched lesions (CT-positive/[68Ga]Ga-DOTA-SSA-negative). PRRT was recommended for second line treatment for gastrointestinal NET with [68Ga]Ga-DOTA-SSA uptake in all lesions, in G1/G2 NET at disease progression, and in a subset of G3 NET provided all lesions are positive at [18F]FDG and [68Ga]Ga-DOTA-SSA. PRRT rechallenge may be used for in patients with stable disease for at least one year after therapy completion. An international consensus is not only a prelude to a more standardized management across countries but also serves as a guide for the direction to follow when designing new research studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ejca.2021.01.008

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

Metadata

Authors
Ambrosini, V., Kunikowska, J., Baudin, E., Bodei, L., Bouvier, C., Capdevila, J., Cremonesi, M., de Herder, W. W., Dromain, C., Falconi, M., Fani, M., Fanti, S., Hicks, R. J., Kabasakal, L., Kaltsas, G., Lewington, V., Minozzi, S., Cinquini, M., Öberg, K., Oyen, W. J. G., O'Toole, D., Pavel, M., Ruszniewski, P., Scarpa, A., Strosberg, J., Sundin, A., Taïeb, D., Virgolini, I., Wild, D., Herrmann, K., & Yao, J.
Venue
European Journal of Cancer
Publisher
Elsevier BV
Published
2021-03
Volume
146
Pages
56-73
ISSN
0959-8049 (ISSN-L)
OpenAlex
W3133235753
Cited by
244
References
10
FWCI
26.81
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.